You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海思科(002653.SZ):獲得創新藥HSK34890片新藥申請《受理通知書》
格隆匯 06-02 11:51

格隆匯6月2日丨海思科(002653.SZ)公佈,公司全資子公司西藏海思科製藥有限公司於近日收到國家藥品監督管理局下發的《受理通知書》,藥品名稱為HSK34890片。

HSK34890是公司自主研發一款極具開發潛力的小分子藥物,能以葡萄糖濃度依賴的方式增強胰島素分泌,改善糖耐量,抑制胰高血糖素分泌,並能夠延緩胃排空,抑制食慾及攝食,從而達到降低血糖的作用,擬用於2型糖尿病(T2DM)的治療。按我國新化學藥品註冊分類規定,其藥品註冊分類為化藥1類。

近年來隨着人們生活方式逐漸改變,我國超重和肥胖人羣迅速增加,糖尿病患病率逐年上升。據統計,1980年我國糖尿病患病率為0.7%,2015-2017年我國成人糖尿病的患病率已達11.2%,其中2型糖尿病(T2DM)最多見,佔90-95%。國際糖尿病聯盟(International Diabetes Faderation, IDF)調查顯示,預計到2045年我國糖尿病患病率將升至12.5%,糖尿病患者將達1.7億,將連續多年位居世界首位。

根據市場調研機構Grand View Research的報吿,全球糖尿病藥物市場規模在2020年達到了197.5億美元。預計到2028年,全球糖尿病藥物市場規模將增長到272.5億美元,複合年增長率為4.3%。結合糖尿病的高發病率,該臨牀需求則更加迫切。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account